cholecystokinin 33 (10-20) has been researched along with vasoactive intestinal peptide in 1 studies
| Studies (cholecystokinin 33 (10-20)) | Trials (cholecystokinin 33 (10-20)) | Recent Studies (post-2010) (cholecystokinin 33 (10-20)) | Studies (vasoactive intestinal peptide) | Trials (vasoactive intestinal peptide) | Recent Studies (post-2010) (vasoactive intestinal peptide) |
|---|---|---|---|---|---|
| 5 | 0 | 0 | 10,873 | 123 | 1,221 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahrén, B; Efendic, S; Sandberg, E; Tendler, D | 1 |
1 other study(ies) available for cholecystokinin 33 (10-20) and vasoactive intestinal peptide
| Article | Year |
|---|---|
Cholecystokinin-33 potentiates and vasoactive intestinal polypeptide inhibits gastric inhibitory polypeptide--induced insulin secretion in the perfused rat pancreas.
Topics: Animals; Cholecystokinin; Drug Interactions; Gastric Inhibitory Polypeptide; Glucose; Insulin; Insulin Secretion; Male; Pancreas; Peptide Fragments; Perfusion; Rats; Rats, Inbred Strains; Vasoactive Intestinal Peptide | 1988 |